This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keaney, J. F. Search for Related Content PubMed PubMed Citation Articles by Keaney, J. F., Jr Related Collections Acute coronary syndromes Related Article

(Circulation. 2005;112:778-780.)
© 2005 American Heart Association, Inc.

Editorial

Circulating Biomarkers in Acute Coronary Syndromes

Something Different or More of the Same?

John F. Keaney, Jr, MD

From the Evans Memorial Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.

Correspondence to Dr John F. Keaney, Jr, Evans Memorial Department of Medicine, Boston University School of Medicine, Boston, MA 02118. E-mail jkeaney@bu.edu

Key Words: Editorials • cardiovascular diseases • troponin • coronary disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

During the past 30 years, there have been significant advances in our treatment of cardiovascular disease, both in the acute setting and in the context of disease prevention.¹ With regard to the former, the availability and safety of acute medical and revascularization strategies for myocardial infarction and unstable angina have reduced both the morbidity and mortality of acute coronary syndromes (ACS).² Acute treatment options are typically resource intensive, however, and up to 50% of patients hospitalized for suspected ACS ultimately leave the hospital with other diagnoses.³ As a consequence, current guidelines for the management of ACS² stress risk stratification as a means for directing invasive versus conservative approaches to patient management.

See p 812

The traditional clinical tools of risk stratification such as history, physical examination, and ECG have proven inadequate in the vast majority of cases. Not surprisingly, this need has spurred considerable investigation into circulating markers that better establish diagnoses and identify high-risk individuals appropriate for the most resource-intensive treatment. From this search, cardiac troponin measurements have emerged as important markers for both ACS diagnosis and identification of future coronary artery disease (CAD) events.² More recently, circulating markers of inflammation such as C-reactive protein,⁴ CD40L,⁵ and myeloperoxidase⁶ have also proven effective in identifying patients with ACS.

In this issue of Circulation, Hayashida and colleagues⁷ have added soluble lectin-like oxidized LDL receptor-1 (sLOX-1) to this expanding list of markers that are associated with ACS. They examined 427 consecutive patients undergoing cardiac catheterization from a single center and measured . . . [Full Text of this Article]

Related Article:

Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis

Kazutaka Hayashida, Noriaki Kume, Takatoshi Murase, Manabu Minami, Daisuke Nakagawa, Tsukasa Inada, Masaru Tanaka, Akira Ueda, Goro Kominami, Hirofumi Kambara, Takeshi Kimura, and Toru Kita
Circulation 2005 112: 812-818. [Abstract] [Full Text]

This article has been cited by other articles:

				V. Palmieri, R. Pini, and M. Chiara Cavallini Pulsology Reloaded: Commentary on Similar Effects of Treatment on Central and Brachial Blood Pressure in Older Hypertensive Subjects Hypertension, June 1, 2007; 49(6): 1210 - 1212. [Full Text] [PDF]